# Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

> **NCT04642469** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Carcinoma, Non- Small Cell Lung

## Interventions

- **DRUG:** Durvalumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04642469
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2023-05-31
- **Final completion:** 2024-01-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04642469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04642469, "Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04642469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*